Department of Medical Oncology, University Hospital of Parma, Parma, 43126, Italy.
Department of Pathological Anatomy & Histology, University Hospital of Parma, Parma, 43126, Italy.
Immunotherapy. 2019 Jan;11(1):21-35. doi: 10.2217/imt-2018-0097.
The knowledge of the immune context of renal cell carcinoma (RCC) is useful to predict benefit from immunotherapy. We retrospectively characterized the immune context of RCC patients underwent primary nephrectomy and pulmonary metastasectomy.
MATERIALS & METHODS: Intratumoral infiltrating lymphocytes and peritumoral renal infiltrating lymphocytes, lymphocyte subpopulations (CD4, CD8), PD-1, PD-L1 were explored in paired samples of primary RCC (T) and respective pulmonary metastases (M).
The immune variables demonstrated intralesional and intratumoral heterogeneity. Intralesional lymphocyte heterogeneity reached 76% of cases in T, 28% in M. The heterogeneity rate for PD-L1 expression was from 44% (T) to 56% (M); it correlated with better survival.
The immune context of RCC is highly variable both within a given tumor and among primary and metastases.
了解肾细胞癌（RCC）的免疫背景有助于预测免疫治疗的获益。本研究回顾性分析了接受根治性肾切除术和肺转移灶切除术的 RCC 患者的免疫背景。
在原发性 RCC（T）及其相应的肺转移灶（M）的配对样本中，研究了肿瘤内浸润淋巴细胞和肿瘤周围肾浸润淋巴细胞、淋巴细胞亚群（CD4、CD8）、PD-1、PD-L1。
免疫变量显示出肿瘤内和肿瘤内异质性。T 中的肿瘤内淋巴细胞异质性达到 76%，M 中为 28%。PD-L1 表达的异质性率从 44%（T）到 56%（M）；与更好的生存相关。
RCC 的免疫背景在同一肿瘤内以及在原发灶和转移灶之间具有高度的可变性。
